Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

SOHO Highlights: State of the Art and Next Questions
14:42

SOHO Highlights: State of the Art and Next Questions

SOHO Highlights on Non-Bulky cHL: Can We Treat Early Disease With Short-Course ABVD w/o RT Based on Negative Interim PET/CT?

FEATURING David Straus
  • 13 views
  • February 23, 2021
09:24

SOHO Highlights: State of the Art and Next Questions

ECHELON-1 Data on Brentuximab Vedotin for Frontline Advanced cHL: Examining A+AVD vs. ABVD

FEATURING David Straus
  • 285 views
  • February 23, 2021
  • 1
10:47

SOHO Highlights: State of the Art and Next Questions

Surveying the Induction and Maintenance Therapy Landscape in Newly Diagnosed, and Approaches to Early R/R MM

FEATURING Sagar Lonial
  • 235 views
  • February 9, 2021
  • 2
20:52

SOHO Highlights: State of the Art and Next Questions

MM State of the Art: Approaches to Smoldering, MRD as a Prognostic Marker, Carfilzomib Frontline, Clonal Evolution, IO

FEATURING Sagar Lonial
  • 27 views
  • February 9, 2021
29:37

SOHO Highlights: State of the Art and Next Questions

CML State of the Art: Dasatinib/Imatinib Dose Optimization, STAMPi Asciminib Efficacy in CP-CML, Treatment Free Remission, Single Cell Analysis

FEATURING Michael Deininger
  • 55 views
  • February 5, 2021
34:50

SOHO Highlights: State of the Art and Next Questions

MPNs State of the Art: What Is the Response to Ruxolitinib vs. BAT? Can We Achieve CHR With Ropeginterferon Alpha-2b in PV? Can We Use Fedratinib in Treatment-Naïve MF?

FEATURING Srdan Verstovsek
  • 158 views
  • February 3, 2021
27:43

SOHO Highlights: State of the Art and Next Questions

MDS State of the Art: Imetelstat/Roxadustat for Anemia, Oral HMAs, Aza Combinations, APR-246 in TP53 Mutations, Magrolimab+Aza in MDS/AML, Enasidenib for HR IDH2 Mutations, Ven+Aza as 1L

FEATURING Guillermo Garcia-Manero
  • 119 views
  • February 3, 2021
  • 1
11:39

SOHO Highlights: State of the Art and Next Questions

Early Stage cHL Management: Bulky vs. Non-bulky Disease, Better Chemotherapy Options to Improve PFS

FEATURING David Straus
  • 166 views
  • February 3, 2021
14:25

SOHO Highlights: State of the Art and Next Questions

SOHO Highlights on Untreated MCL: How Does Deferred Therapy Work? What Are the Chemo-Based Induction Regimens? How Common Is Auto Transplant?

FEATURING Jonathon Cohen
  • 90 views
  • February 3, 2021
19:43

SOHO Highlights: State of the Art and Next Questions

SOHO Highlights on R/R MCL: The Role of BTKis, CAR-T, and Chemotherapy on Treatment Outcomes

FEATURING Jonathon Cohen
  • 149 views
  • February 3, 2021
14:40

SOHO Highlights: State of the Art and Next Questions

Newly Diagnosed ALCL/PTCL State of the Art: How Can We Improve Outcomes in PTCL? Does 1L Brentuximab Vedotin Improve PFS? Is Consolidative SCT Beneficial?

FEATURING Kerry Savage
  • 118 views
  • February 3, 2021
20:07

SOHO Highlights: State of the Art and Next Questions

R/R PTCL State of the Art: Allo-SCT vs. Auto-SCT? Can Pralatrexate Change the Tumor Volume? Does Duvelisib+Romidepsin Increase ORR?

FEATURING Kerry Savage
  • 16 views
  • February 3, 2021
13:36

SOHO Highlights: State of the Art and Next Questions

SOHO Updates on 1L FL: Does RT+/-(R)CVP Improve PFS in Limited Stage Disease? Is W&W Appropriate for Asymptomatic Advanced Disease? Should We Use G-Chemo vs. R-Chemo in CD20+ iNHL?

FEATURING Robert Marcus
  • 109 views
  • February 3, 2021
  • 1
18:07

SOHO Highlights: State of the Art and Next Questions

SOHO Updates on 1L MZL: Can RT Help in Early Stage MALToma? Is R-Benda Superior to R-CHOP in Advanced Disease? Is Rituximab Mono a Good Maintenance Choice?

FEATURING Robert Marcus
  • 12 views
  • February 3, 2021
34:46

SOHO Highlights: State of the Art and Next Questions

DLBCL State of the Art: Does Gene Expression Help With the Disease? Can We Use R-CHOP in PIK3CD-Mutated Patients? Is CAR-T a “Game Changer”? How to Incorporate Genomics?

FEATURING Sandeep Dave
  • 115 views
  • February 3, 2021
  • 1
24:38

SOHO Highlights: State of the Art and Next Questions

Dana-Farber CLL State of the Art: A Review of BTK Inhibitors Data in the Frontline Setting

FEATURING Jennifer Brown
  • 218 views
  • February 2, 2021
24:52

SOHO Highlights: State of the Art and Next Questions

CAR-T State of the Art: What Therapies Will Be Available in the Next 5 Years? Will CAR-T Replace Transplant?

FEATURING Sergio Giralt
  • 33 views
  • February 2, 2021
29:51

SOHO Highlights: State of the Art and Next Questions

AML State of the Art: Older Patients Management, MRD, Total Oral Combination Therapy, Triplet Therapy, Best Sequencing Strategies, Incorporation of Maintenance Therapy, Overcoming Mechanisms of Action, Immunotherapy

FEATURING Amer Zeidan
  • 116 views
  • February 2, 2021
29:28

SOHO Highlights: State of the Art and Next Questions

ALL State of the Art at MD Anderson: Hyper-CVAD Combinations, MiniHCVD-Ino-Blina Combo, AlloHSCT

FEATURING Hagop Kantarjian
  • 33 views
  • February 2, 2021